{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:08:56Z","timestamp":1790629736184,"version":"4.1.0"},"reference-count":158,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s575152","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T14:45:15Z","timestamp":1777992315000},"page":"1-32","source":"Crossref","is-referenced-by-count":2,"title":["Advances in PARP Inhibition in Improving Outcomes of Breast Cancer, Ovarian Cancer, and Other Solid Tumors: Journey of Discovery, Development, and Clinical Updates of Talazoparib"],"prefix":"10.2147","volume":"Volume 20","author":[{"given":"Muhammad","family":"Latif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Mazhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mussarat","family":"Tasleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmajeed","family":"Alqurashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Arfan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaman","family":"Ashraf \u200e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"Siegel","year":"2024","journal-title":"Ca a Cancer J Clin"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","volume":"31","author":"Kim","year":"2025","journal-title":"Nat Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/CM9.0000000000003921","volume":"139","author":"Gu","year":"2026","journal-title":"Chinese Med J"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"9347","DOI":"10.1038\/s41598-025-93883-9","volume":"15","author":"Cai","year":"2025","journal-title":"Sci Rep"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S1470-2045(11)70141-3","volume":"12","author":"Sullivan","year":"2011","journal-title":"Lancet Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3322\/caac.21863","volume":"74","author":"Star","year":"2024","journal-title":"Ca a Cancer J Clin"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3322\/caac.21863","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1093\/jnci\/90.23.1824","volume":"90","author":"Claus","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/jnci\/91.11.943","volume":"91","author":"Peto","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1126\/science.2270482","volume":"250","author":"Hall","year":"1990","journal-title":"Science"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1126\/science.7545954","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/378789a0","volume":"378","author":"Wooster","year":"1995","journal-title":"Nature"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1126\/science.8091231","volume":"265","author":"Wooster","year":"1994","journal-title":"Science"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/ng0594-103","volume":"7","author":"Stratton","year":"1994","journal-title":"Nat Genet"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/jnci\/95.3.214","volume":"95","author":"Hahn","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ijc.10155","volume":"98","author":"Iscovich","year":"2002","journal-title":"Int J Cancer"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1158\/1078-0432.CCR-03-0604","volume":"10","author":"Kirchhoff","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/0140-6736(91)90076-2","volume":"338","author":"Narod","year":"1991","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/jnci\/djh008","volume":"96","author":"Niell","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ng0597-17","volume":"16","author":"Ozcelik","year":"1997","journal-title":"Nat Genet"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1006\/gyno.1999.5623","volume":"76","author":"Zweemer","year":"2000","journal-title":"Gynecologic Oncol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/nature08657","volume":"462","author":"Galanty","year":"2009","journal-title":"Nature"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/nature08593","volume":"462","author":"Morris","year":"2009","journal-title":"Nature"},{"key":"ref27","first-page":"4842","volume":"61","author":"Moynahan","year":"2001","journal-title":"Cancer Res"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1097-2765(00)80035-0","volume":"1","author":"Patel","year":"1998","journal-title":"Mol Cell"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/sj.bjc.6600859","volume":"88","author":"Tassone","year":"2003","journal-title":"Br J Cancer"},{"key":"ref30","first-page":"3547","volume":"59","author":"Yuan","year":"1999","journal-title":"Cancer Res"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1126\/science.285.5428.747","volume":"285","author":"Zhong","year":"1999","journal-title":"Science"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1524-4741.2008.00665.x","volume":"15","author":"Schwartz","year":"2009","journal-title":"The Breast Journal"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/jnci\/94.18.1365","volume":"94","author":"Brose","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"ref34","first-page":"678","volume":"52","author":"Easton","year":"1993","journal-title":"Am J Hum Genet"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.1088759","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"5837","DOI":"10.1038\/sj.onc.1209875","volume":"25","author":"Honrado","year":"2006","journal-title":"Oncogene"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/jnci\/djg050","volume":"95","author":"Foulkes","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1200\/JCO.2004.05.055","volume":"22","author":"Liede","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1093\/carcin\/bgs132","volume":"33","author":"Sousa","year":"2012","journal-title":"Carcinogenesis"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1158\/2159-8290.CD-13-0891","volume":"4","author":"Hu","year":"2014","journal-title":"Cancer Discov"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"6170","DOI":"10.1093\/nar\/gkl840","volume":"34","author":"Wang","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1200\/JCO.2014.58.8848","volume":"33","author":"Scott","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1084\/jem.20082468","volume":"206","author":"Robert","year":"2009","journal-title":"J Exp Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"6380","DOI":"10.1093\/nar\/gku298","volume":"42","author":"Soni","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"17860","DOI":"10.1074\/jbc.274.25.17860","volume":"274","author":"Ame","year":"1999","journal-title":"J Biol Chem"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"23028","DOI":"10.1074\/jbc.M202390200","volume":"277","author":"Schreiber","year":"2002","journal-title":"J Biol Chem"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.molcel.2010.12.006","volume":"41","author":"Rulten","year":"2011","journal-title":"Mol Cell"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/bjc.2016.311","volume":"115","author":"Konecny","year":"2016","journal-title":"Br J Cancer"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1741-7015-10-25","volume":"10","author":"Kummar","year":"2012","journal-title":"BMC Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.mam.2013.01.006","volume":"34","author":"Curtin","year":"2013","journal-title":"Mol Aspect Med"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1111\/febs.12298","volume":"280","author":"Ekblad","year":"2013","journal-title":"FEBS J"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.bbcan.2014.07.004","volume":"1846","author":"Lupo","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1158\/1535-7163.MCT-06-0552","volume":"6","author":"Thomas","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1021\/jm020259n","volume":"45","author":"Canan Koch","year":"2002","journal-title":"J Med Chem"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"6581","DOI":"10.1021\/jm8001263","volume":"51","author":"Menear","year":"2008","journal-title":"J Med Chem"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","volume":"13","author":"Donawho","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"6965","DOI":"10.1016\/j.bmc.2008.05.044","volume":"16","author":"Penning","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1021\/jm801171j","volume":"52","author":"Penning","year":"2009","journal-title":"J Med Chem"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"7170","DOI":"10.1021\/jm901188v","volume":"52","author":"Jones","year":"2009","journal-title":"J Med Chem"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1021\/jm5018237","volume":"58","author":"Jones","year":"2015","journal-title":"J Med Chem"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-13-1391","volume":"19","author":"Shen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12916-015-0425-1","volume":"13","author":"Livraghi","year":"2015","journal-title":"BMC Med"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/0005-2787(71)90012-8","volume":"238","author":"Clark","year":"1971","journal-title":"Biochimica Et Biophysica Acta"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/283593a0","volume":"283","author":"Durkacz","year":"1980","journal-title":"Nature"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10549-019-05305-w","volume":"177","author":"Di\u00e9ras","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.1200\/JCO.2014.55.2984","volume":"32","author":"O\u2019Shaughnessy","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ijrobp.2020.09.032","volume":"109","author":"Loap","year":"2021","journal-title":"Int J Radiation Oncol*Biol*Phys"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"11782234221080553","DOI":"10.1177\/11782234221080553","volume":"16","author":"Kawanishi","year":"2022","journal-title":"Breast Cancer"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1080\/07357900802709159","volume":"27","author":"Bedikian","year":"2009","journal-title":"Cancer Invest"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11239-008-0230-1","volume":"27","author":"Morrow","year":"2009","journal-title":"J Thrombosis Thrombolysis"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/med.22069","volume":"45","author":"Bai","year":"2025","journal-title":"Med Res Rev"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"15541","DOI":"10.1021\/acs.jmedchem.0c01346","volume":"63","author":"Wang","year":"2020","journal-title":"J Med Chem"},{"key":"ref73","first-page":"608","volume":"9","author":"Han","year":"2019","journal-title":"Am J Cancer Res"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1158\/1078-0432.CCR-20-3546","volume":"27","author":"Li","year":"2021","journal-title":"Clin Cancer Res"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41598-023-50630-2","volume":"14","author":"Jeon","year":"2024","journal-title":"Sci Rep"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41416-022-02022-y","volume":"128","author":"Kristeleit","year":"2023","journal-title":"Br J Cancer"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1158\/1538-7445.AM2022-2609","volume":"82","author":"Jamal","year":"2022","journal-title":"Cancer Res"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrc2812","volume":"10","author":"Rouleau","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1200\/JCO.23.02182","volume":"42","author":"Heiss","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(25)00684-1","volume":"406","author":"Agarwal","year":"2025","journal-title":"Lancet"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(25)00683-X","volume":"406","author":"Fizazi","year":"2025","journal-title":"Lancet"},{"key":"ref83","unstructured":"Pfizer provides update on U.S. regulatory review of Talzenna in combination with Xtandi for broader use in metastatic castration-resistant prostate cancer. News release. Pfizer; 2025. Available from: https:\/\/www.pfizer.com\/news\/announcements\/pfizer-provides-update-us-regulatory-review-talzenna-combination-xtandi-broader. Accessed Feb 22, 2026."},{"key":"ref84","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1021\/acs.jmedchem.5b01498","volume":"59","author":"Wang","year":"2016","journal-title":"J Med Chem"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/13543776.2017.1259413","volume":"27","author":"Yuan","year":"2017","journal-title":"Expert Opin Ther Patents"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"115758","DOI":"10.1016\/j.ejmech.2023.115758","volume":"260","author":"Sheikhi","year":"2023","journal-title":"Eur J Med Chem"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"7522","DOI":"10.1200\/jco.2014.32.15_suppl.7522","volume":"32","author":"Wainberg","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","volume":"13","author":"Murai","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res"},{"key":"ref90","unstructured":"Yong X, Yohi PW, Xu M, Cruise D, Huang L. Synthesis of PARP inhibitor Talazoparib. 2017. (WO2017215166A1)."},{"key":"ref91","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/molecules25020407","volume":"25","author":"Li","year":"2020","journal-title":"Molecules"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.pharmthera.2016.03.003","volume":"161","author":"Li","year":"2016","journal-title":"Pharmacol Ther"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-0-387-74039-3_1","volume":"608","author":"Gonzalez-Angulo","year":"2007","journal-title":"Adv Exp Med Biol"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ctrv.2008.01.007","volume":"34","author":"Coley","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-62703-541-5_1","volume":"1045","author":"Sassoon","year":"2013","journal-title":"Methods Mol Biol"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1146\/annurev-med-050311-201823","volume":"64","author":"Sievers","year":"2013","journal-title":"Ann Rev Med"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.cbpa.2010.06.170","volume":"14","author":"Alley","year":"2010","journal-title":"Curr Opin Chem Biol"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2015.04.003","volume":"364","author":"Andrei","year":"2015","journal-title":"Cancer Lett"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1007\/s12282-022-01390-w","volume":"29","author":"Kotani","year":"2022","journal-title":"Breast Cancer"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1158\/1078-0432.CCR-18-1891","volume":"25","author":"Turner","year":"2019","journal-title":"Clin Cancer Res"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1200\/JCO.19.01304","volume":"38","author":"Litton","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref102","unstructured":"Phase II talazoparib in BRCA1 +BRCA2 wild-type & triple-neg\/HER2-negative breast cancer\/solid tumors. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02401347. Accessed May 31, 2024."},{"key":"ref103","doi-asserted-by":"publisher","first-page":"e439","DOI":"10.1634\/theoncologist.2019-0493","volume":"25","author":"Hurvitz","year":"2020","journal-title":"Oncologist"},{"key":"ref104","unstructured":"I-SPY TRIAL: neoadjuvant and personalized adaptive novel agents to treat breast cancer. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01042379. Accessed May 31, 2024."},{"key":"ref105","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.euo.2023.10.017","volume":"7","author":"Kotecha","journal-title":"European Urol Oncol"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/oncolo\/oyad139","volume":"28","author":"Litton","year":"2023","journal-title":"Oncologist"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"101584","DOI":"10.1016\/j.esmoop.2023.101584","volume":"8","author":"Ahnert","year":"2023","journal-title":"ESMO Open"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/s43018-022-00439-1","volume":"3","author":"Gruber","year":"2022","journal-title":"Nat Cancer"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.4143\/crt.2020.1381","volume":"53","author":"Lee","year":"2021","journal-title":"Cancer Res Treat"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","volume":"31","author":"Litton","year":"2020","journal-title":"Ann Oncol"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/jcph.1626","volume":"60","author":"Elmeliegy","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/jcph.1623","volume":"60","author":"Yu","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejca.2018.09.003","volume":"104","author":"Hurvitz","year":"2018","journal-title":"Eur J Cancer"},{"key":"ref114","unstructured":"Phase II talazoparib in BRCA1 +BRCA2 wild-type & triple-neg\/HER2-negative breast cancer\/solid tumors. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02401347. Accessed August 02, 2024."},{"key":"ref115","unstructured":"I-SPY 2 TRIAL: neoadjuvant and personalized adaptive novel agents to treat breast cancer (I-SPY 2). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01042379. Accessed August 02, 2024."},{"key":"ref116","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1158\/2159-8290.CD-16-1250","volume":"7","author":"de Bono","year":"2017","journal-title":"Cancer Discov"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"6400","DOI":"10.1158\/1078-0432.CCR-17-0703","volume":"23","author":"Dhawan","year":"2017","journal-title":"Clin Cancer Res"},{"key":"ref118","unstructured":"Talazoparib in determining genetic effects on disease response in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer (POSITION). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02316834. Accessed August 02, 2024."},{"key":"ref119","unstructured":"A phase 2, multiple-cohort, open-label, international study of talazoparib monotherapy and talazoparib plus temozolomide in women with relapsed ovarian, fallopian tube, and peritoneal cancer. I. Myriad Genetic Laboratories, I. Medivation; 2016."},{"key":"ref120","unstructured":"A phase 2 pilot study of BMN 673 (Talazoparib), an oral PARP inhibitor, in patients with deleterious BRCA1\/2 mutation-associated ovarian cancer who have had prior PARP inhibitor treatment. 2014."},{"key":"ref121","unstructured":"Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations in BRCA1\/2, mutations\/deletions in other BRCA pathway genes and germline mutation in BRCA1\/2 (Not breast or ovarian cancer). I. National Cancer; 2014."},{"key":"ref122","unstructured":"Pilot trial of BMN 673, an oral PARP inhibitor, in patients with advanced solid tumors and deleterious BRCA mutations. 2013."},{"key":"ref123","unstructured":"A phase I study of single agent talazoparib (BMN 673) in advanced cancer patients with hepatic and renal dysfunction. 2015."},{"key":"ref124","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discovery"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00280-023-04600-0","volume":"93","author":"Mittra","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s10637-023-01351-w","volume":"41","author":"Luo","year":"2023","journal-title":"Invest New Drugs"},{"key":"ref127","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamaoncol.2022.5218","volume":"9","author":"Schram","year":"2023","journal-title":"JAMA Oncol"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamaoncol.2022.5228","volume":"9","author":"Yap","year":"2023","journal-title":"JAMA Oncol"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1002\/cam4.4724","volume":"11","author":"Leal","year":"2022","journal-title":"Cancer Med"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s40262-020-00983-y","volume":"60","author":"Durairaj","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1007\/s10637-021-01120-7","volume":"39","author":"Naito","year":"2021","journal-title":"Invest New Drugs"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"e28073","DOI":"10.1002\/pbc.28073","volume":"67","author":"Schafer","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/jcph.1415","volume":"59","author":"Yu","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1158\/1078-0432.CCR-22-1553","volume":"29","author":"Wainberg","year":"2023","journal-title":"Clin Cancer Res"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.cllc.2021.01.001","volume":"22","author":"Owonikoko","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"ref136","unstructured":"Phase 1, two-arm, open-label study of once daily, oral Bmn 673 in patients with advanced hematological malignancies. I. Medivation; 2011."},{"key":"ref137","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ejca.2020.06.014","volume":"137","author":"Federico","year":"2020","journal-title":"Eur J Cancer"},{"key":"ref138","unstructured":"A phase 1B\/2 study to evaluate safety and anti tumor activity of avelumab in combination with the poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor talazoparib in patients with locally advanced or metastatic solid tumors. 2017."},{"key":"ref139","doi-asserted-by":"publisher","first-page":"e2400026","DOI":"10.1200\/PO.24.00026","volume":"8","author":"Srkalovic","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"ref140","unstructured":"TALAPRO-1: a phase 2, open-label, response rate study of talazoparib in men with dna repair defects and metastatic castration-resistant prostate cancer who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal agent (Enzalutamide and\/or abiraterone acetate\/prednisone). I. Medivation; 2017."},{"key":"ref141","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/bcp.14178","volume":"86","author":"Elmeliegy","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"ref142","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1158\/1541-7786.MCR-15-0191-T","volume":"13","author":"Hopkins","year":"2015","journal-title":"Mol Cancer Res"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1200\/jco.2013.31.15_suppl.2580","volume":"31","author":"De Bono","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref144","doi-asserted-by":"publisher","first-page":"CT011","DOI":"10.1158\/1538-7445.AM2016-CT011","volume":"76","author":"Wainberg","year":"2016","journal-title":"Cancer Res"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/pbc.25201","volume":"62","author":"Smith","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"ref146","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1200\/jco.2013.31.15_suppl.2580","volume":"31","author":"De Bono","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref147","doi-asserted-by":"publisher","first-page":"TPS1108","DOI":"10.1200\/jco.2015.33.15_suppl.tps1108","volume":"33","author":"Turner","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref148","doi-asserted-by":"publisher","first-page":"TPS1107","DOI":"10.1200\/jco.2015.33.15_suppl.tps1107","volume":"33","author":"Litton","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref149","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1200\/JCO.2017.35.15_suppl.1007","volume":"35","author":"Turner","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref150","unstructured":"A phase 2, 2-stage, 2-cohort study of talazoparib (BMN 673) administered to germline BRCA mutation subjects with locally advanced and\/or metastatic breast cancer. I. Myriad Genetic Laboratories, I. Medivation; 2014."},{"key":"ref151","doi-asserted-by":"publisher","first-page":"OT1\u201303","DOI":"10.1158\/1538-7445.SABCS15-OT1-03-16","volume":"76","author":"Litton","year":"2016","journal-title":"Cancer Res"},{"key":"ref152","unstructured":"A phase 3, open-label, randomized parallel, 2-arm, multi-center study of talazoparib(BMN 673) versus physician\u2019s choice in germline BRCA mutation subjects with locally advanced and\/or metastatic breast cancer, who have received prior chemotherapy regimens for metastatic disease. I. Medivation; 2013."},{"key":"ref153","doi-asserted-by":"publisher","first-page":"6839","DOI":"10.1158\/1078-0432.CCR-19-0317","volume":"25","author":"Liu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"ref154","doi-asserted-by":"publisher","first-page":"69105","DOI":"10.18632\/oncotarget.19079","volume":"8","author":"Lesueur","year":"2017","journal-title":"Oncotarget"},{"key":"ref155","unstructured":"Phase 2 trial of the Combination of the BET inhibitor, ZEN003694 (ZEN-3694), and the PARP inhibitor talazoparib, in patients with molecularly-selected solid tumors (ComBET). 2022."},{"key":"ref156","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1007\/s00432-022-04269-7","volume":"148","author":"Chatterjee","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref157","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s12032-023-02222-3","volume":"40","author":"Das","year":"2023","journal-title":"Med Oncol"},{"key":"ref158","doi-asserted-by":"publisher","first-page":"5629","DOI":"10.3390\/ijms25115629","volume":"25","author":"Mentzel","year":"2024","journal-title":"Int J Mol Sci"}],"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/114864","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/114864","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T14:45:33Z","timestamp":1777992333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/advances-in-parp-inhibition-in-improving-outcomes-of-breast-cancer-ova-peer-reviewed-fulltext-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":158,"URL":"https:\/\/doi.org\/10.2147\/dddt.s575152","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}